These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

300 related items for PubMed ID: 11830753

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Antiplatelet therapy using cilostazol, a specific PDE3 inhibitor.
    Ikeda Y.
    Thromb Haemost; 1999 Aug; 82(2):435-8. PubMed ID: 10605734
    [No Abstract] [Full Text] [Related]

  • 4. Comparison of the effects of cilostazol and milrinone on intracellular cAMP levels and cellular function in platelets and cardiac cells.
    Cone J, Wang S, Tandon N, Fong M, Sun B, Sakurai K, Yoshitake M, Kambayashi J, Liu Y.
    J Cardiovasc Pharmacol; 1999 Oct; 34(4):497-504. PubMed ID: 10511123
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Cilostazol: treatment of intermittent claudication.
    Reilly MP, Mohler ER.
    Ann Pharmacother; 2001 Jan; 35(1):48-56. PubMed ID: 11197586
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Inhibition of shear stress-induced platelet aggregation by cilostazol, a specific inhibitor of cGMP-inhibited phosphodiesterase, in vitro and ex vivo.
    Minami N, Suzuki Y, Yamamoto M, Kihira H, Imai E, Wada H, Kimura Y, Ikeda Y, Shiku H, Nishikawa M.
    Life Sci; 1997 Jan; 61(25):PL 383-9. PubMed ID: 9416770
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Cilostazol in the management of vascular disease.
    Dalainas I.
    Int Angiol; 2007 Mar; 26(1):1-7. PubMed ID: 17353881
    [Abstract] [Full Text] [Related]

  • 14. Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture.
    Takahashi S, Oida K, Fujiwara R, Maeda H, Hayashi S, Takai H, Tamai T, Nakai T, Miyabo S.
    J Cardiovasc Pharmacol; 1992 Dec; 20(6):900-6. PubMed ID: 1282592
    [Abstract] [Full Text] [Related]

  • 15. Cilostazol, an inhibitor of type 3 phosphodiesterase, produces endothelium-independent vasodilation in pressurized rabbit cerebral penetrating arterioles.
    Nakamura K, Ikomi F, Ohhashi T.
    J Vasc Res; 2006 Dec; 43(1):86-94. PubMed ID: 16286783
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Differential effects of phosphodiesterase PDE-3/PDE-4-specific inhibitors on vasoconstriction and cAMP-dependent vasorelaxation following balloon angioplasty.
    Zhao H, Quilley J, Montrose DC, Rajagopalan S, Guan Q, Smith CJ.
    Am J Physiol Heart Circ Physiol; 2007 Jun; 292(6):H2973-81. PubMed ID: 17293498
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Comparison of the effects of cilostazol and milrinone on cAMP-PDE activity, intracellular cAMP and calcium in the heart.
    Shakur Y, Fong M, Hensley J, Cone J, Movsesian MA, Kambayashi J, Yoshitake M, Liu Y.
    Cardiovasc Drugs Ther; 2002 Sep; 16(5):417-27. PubMed ID: 12652111
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.